|
Cancer is a pervasive and dangerous issue that has a profound influence on society. However, there are currently no treatments for curing cancer because of the hard diagnosis and the variability of cancer cells. In addition to addressing the problems, numerous innovative methods have been developed, such as immunotherapies. Chimeric antigen receptor (CAR) T cell therapy is one of the various types in them that have quickly gained popularity in modern times and might be a beacon of hope in healing cancer. This is a brand-new approach to precisely target tumor treatment. Through modification and refinement, it has shown positive outcomes in clinical trials in recent years. The highly effective tumor immunotherapy technique has promise that may completely eradicate cancer. Nevertheless, limitations existed in CAR-T cell therapy which leaves many uncertainties. The effectiveness and safety of CAR-T therapy have always been attached to great attention. Not only the unsuccessful or tough manufacturing and resistance but also the severe side effect and relapse are shown in this treatment. The therapy cannot make sure that do not affect healthy human cells bringing deterioration or long-term suffering to the patient. Meanwhile, the restrictions on solid tumors block the steps on general usage in cancer treatment. The study of the key factors and the evolution of CAR design is necessary to tackle the challenges as a result. In this article, the mechanism behind the limitations and the latest strategies to overcome them are highlighted to broaden the clinical efficacy.
|
